On November 21, 2023, Gelonghui reported that wanbangde pharmaceutical holding group (002082.SZ) stated on its investor interaction platform that the company has been laying out overseas markets for many years. 1. In the medical device business, the company continues to promote the "bringing in and going out" strategy of China-Africa synergistic development. In 2016, it acquired South African companies ThermaCare and Elite, starting in-depth cooperation with the South African medical industry. The focus is on spinal fusion devices, orthopedic implants, medical devices, and hospital engineering services. It acts as an agent for several internationally and domestically renowned brands in the African market for the sale and maintenance services of medical devices such as PET-CT and magnetic resonance imaging, and the "China-Africa Medical Industry Park" was officially put into use in 2019. 2. In 2021, a subsidiary in the usa was established to connect overseas pharmaceutical research and registration. Currently, the drug physostigmine methyl sulfate appropriate for myasthenia gravis and neonatal hypoxic-ischemic encephalopathy, classified as an "orphan drug," as well as treatments for "rare pediatric diseases" related to neonatal hypoxic-ischemic encephalopathy have been recognized by the FDA. Preparations for the IND application are currently underway. Meanwhile, several disposable medical polymer consumables have already obtained FDA 510(K) recognition. Some active pharmaceutical ingredients of the company have commenced overseas sales operations.